"With people in the U.S. with AIDS expected to live close to a normal life span, the majority of pharmaceutical companies are not developing innovative new long-term treatment options that offer improved efficacy, safety and tolerability.
"The ATAC Pharmaceutical Company HIV/AIDS Report Card evaluates the nine largest HIV/AIDS drug-producing pharmaceutical companies in five categories: drug development portfolio and plans, access to drugs, pricing, community relations and marketing practices. The average final grade was a C-. See below for how ATAC ranked each of the companies on the five categories, and view the additional resources for more information."
Read more in ATAC-USA.org, September 10, 2009.
0 comments:
Post a Comment